HT
LGND icon

HAP Trading’s Ligand Pharmaceuticals LGND Stock Holding History

HAP Trading’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-21,225
Closed -$1.8M – 1246
2018
Q4 		$1.8M Buy
+21,225
New +$2.26M 0.11% 162
2017
Q1 		– Sell
-18,446
Closed -$1.17M – 1180
2016
Q4 		$1.17M Buy
+18,446
New +$1.16M 0.06% 231
2014
Q1 		– Sell
-37,241
Closed -$1.55M – 1223
2013
Q4 		$1.22M Buy
+37,241
New +$1.21M 0.04% 375

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HAP Trading's LGND Position: Q1 2019 in Review

HAP Trading sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 21,225 shares — an estimated $1.8M sold.

HAP Trading first reported a position in LGND in Q4 2013 and held it in 3 quarters. The position peaked at $1.8M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • HAP Trading reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • HAP Trading sold 21,225 Ligand Pharmaceuticals shares in Q1 2019, an estimated $1.8M.
  • HAP Trading first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • HAP Trading's Ligand Pharmaceuticals position peaked at $1.8M in Q4 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on HAP Trading's 13F filing for Q1 2019, filed 10 May 2019.